ESMO26: Standard dosing prevails over 12-week checkpoint inhibitors in MOIO trial - Pharmaceutical Technology

Reduced-frequency checkpoint inhibitor treatment could not demonstrate non-inferior PFS and showed a signal of worse survival. Reduced-frequency checkpoint inhibitor treatment could not demonstrate non-inferior PFS and showed a signal of worse survival. The MOIO study compared immune checkpoint inhibitor (ICI) dosing with reduced-frequency dosing in patients with locally advanced or metastatic solid tumours who responded after six months of ICI therapy. Image credit: [SeventyFour]/Shutterstock.com Unlock FREE Access to Premium Content ​Discover exclusive forecasts, analyst insights, and in-depth pharmaceutical industry analysis spanning drug development, manufacturing, regulation, and global healthcare trends. With a free Pharmaceutical Technology profile, you can: The leading site…

Source: Pharmaceutical Technology